MX2019001811A - Prevencion y tratamiento de enfermedades de calcificacion vascular y enfermedades asociadas con lo cardiovascular. - Google Patents

Prevencion y tratamiento de enfermedades de calcificacion vascular y enfermedades asociadas con lo cardiovascular.

Info

Publication number
MX2019001811A
MX2019001811A MX2019001811A MX2019001811A MX2019001811A MX 2019001811 A MX2019001811 A MX 2019001811A MX 2019001811 A MX2019001811 A MX 2019001811A MX 2019001811 A MX2019001811 A MX 2019001811A MX 2019001811 A MX2019001811 A MX 2019001811A
Authority
MX
Mexico
Prior art keywords
agent
activity
modulates expression
reducing
cells
Prior art date
Application number
MX2019001811A
Other languages
English (en)
Inventor
Majeti Satyanarayana
Mehansho Haile
Egziabher Tzeghai Ghebre
Original Assignee
Summit Innovation Labs LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Summit Innovation Labs LLC filed Critical Summit Innovation Labs LLC
Publication of MX2019001811A publication Critical patent/MX2019001811A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención abarca composiciones y métodos para interferir efectivamente, reducir y prevenir la conversión de células de músculo liso vascular (VSMC) y células troncales en circulación a células osteoblásticas similares a hueso, reduciendo y/o previniendo así la calcificación vascular (VC) o la deposición de calcio mineral (hidroxiapatita) en la vasculatura. La severidad y extensión de calcificación en las arterias principales reflejan la carga de placa arterioesclerótica y predicen fuertemente la morbilidad y mortalidad cardiovascular. Las composiciones de invención de la presente utilizadas para su administración en humanos y otros sujetos mamíferos comprenden activos seleccionados que inhiben, interfieren o regulan procesos bioquímicos que conducen a dicha calcificación e incluyen (1) al menos un agente que modula la expresión y/o la actividad del receptor gamma de proteína activado por peroxisoma (PPAR-?); (2) al menos un agente que modula la expresión y/o actividad de uno o más factores de transcripción osteogénicos (Cbfa1/Tunx2, Osterix, Msx2) y/o la señalización de ß catenina; (3) al menos un agente que modula la expresión y/o actividad de una o más de las protéínas morfogenéticas de hueso (BMP: BMP 2 y 4), fosfatasa alcalina (ALP) y osteocalcina; (4) al menos un agente que inhibe la actividad de especies reactivas de oxígeno (ROS); y (5) al menos un agente que suprime uno o más de los mediadores inflamatorios incluyendo interleucinas IL-1a, lL-1ß, lL-6, NF-kB, TNF-a, metaloproteinasas de matriz (MMP) y prostaglandina E2 (PGE2). Las composiciones además pueden comprender al menos un agente que promueve la expresión y/o carboxilación de la proteína Gla de matriz (MGP). A modo de ventaja, estos activos seleccionados incluyen materiales tales como fitonutrientes, vitaminas y minerales que se han utilizado ampliamente en productos alimenticios y en bebidas y son seguros para el consumo humano y de mascotas/animales. Las composiciones con dichas combinaciones poseen la habilidad de prevenir, tratar y revertir VC no sólo en arterias coronarias sino también en otros tejidos capaces de someterse a calcificación indeseada. Además, las composiciones de la presente son efectivas contra condiciones asociadas o factores/inductores que contribuyen a VC y enfermedad cardiovascular, incluyendo diabetes, obesidad, hipertensión, inflamación, estrés oxidante, osteoporosis y artritis.
MX2019001811A 2016-08-15 2017-07-24 Prevencion y tratamiento de enfermedades de calcificacion vascular y enfermedades asociadas con lo cardiovascular. MX2019001811A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662374983P 2016-08-15 2016-08-15
US15/649,084 US11344575B2 (en) 2016-08-15 2017-07-13 Vascular calcification prevention and treatment
PCT/US2017/043432 WO2018034797A1 (en) 2016-08-15 2017-07-24 Vascular calcification and cardiovascular/associated diseases prevention and treatment

Publications (1)

Publication Number Publication Date
MX2019001811A true MX2019001811A (es) 2019-08-21

Family

ID=61160003

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019001811A MX2019001811A (es) 2016-08-15 2017-07-24 Prevencion y tratamiento de enfermedades de calcificacion vascular y enfermedades asociadas con lo cardiovascular.

Country Status (7)

Country Link
US (1) US11344575B2 (es)
EP (1) EP3496844B1 (es)
CN (1) CN109641183B (es)
AU (1) AU2017312737B2 (es)
CA (1) CA3032792A1 (es)
MX (1) MX2019001811A (es)
WO (1) WO2018034797A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11911349B2 (en) 2018-03-30 2024-02-27 Nattopharma As Rapidly improving vascular conditions by administering vitamin K
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
AU2020277763A1 (en) * 2019-05-22 2021-12-16 Biocompatibility Innovation Srl Method for preventing the formation of calcified deposits and for inactivating xenoantigens in biological matrices
CN110818553B (zh) * 2019-10-17 2022-06-14 青海师范大学 一种小叶金钱草抗炎化合物及其制备方法
CN111184914B (zh) * 2020-02-17 2021-10-15 四川大学 一种功能化脱细胞基质生物材料及其制备方法和应用
KR102537016B1 (ko) * 2020-12-02 2023-05-26 목포대학교산학협력단 니클로사마이드를 포함하는 판막 석회화 예방 또는 치료용 조성물
CN113637021B (zh) * 2021-08-18 2022-07-15 云南大学 一种活性化合物及其提取方法和应用、药物组合物及其应用
CN114748486A (zh) * 2022-03-25 2022-07-15 南京盛德生物科技研究院有限公司 一种含有维生素k2改善心血管钙化的药物组合物及其制备方法与应用
CN115920059B (zh) * 2023-02-20 2023-05-26 广东金骏康生物技术有限公司 一种fxr受体抑制组合物、制备方法及其防治冠状病毒的应用
CN117257805B (zh) * 2023-11-10 2024-03-12 中山大学附属第八医院（深圳福田） 核苷类逆转录酶抑制剂在制备抗血管钙化药物中的应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217342A (en) * 1977-12-19 1980-08-12 Colgate Palmolive Company Magnesium polycarboxylate complexes as anticalculus agents
US5849337A (en) 1997-06-27 1998-12-15 Gusty Winds Corporation Method of enhancing magnesium absorption and prevention of atherosclerosis
US6210701B1 (en) * 1999-04-30 2001-04-03 Healthcomm International, Inc. Medical food for treating inflammation-related diseases
US6716829B2 (en) * 2000-07-27 2004-04-06 Pharmacia Corporation Aldosterone antagonist and cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation-related cardiovascular disorders
UA77660C2 (en) 2000-10-03 2007-01-15 Compositions and methods for reducing plasma lipoprotein a level in human
CN1649574A (zh) * 2002-02-15 2005-08-03 Dsmip资产公司 用于治疗和预防血管发生相关性病变的包含蕃茄红素的组合物
GB0220182D0 (en) 2002-08-30 2002-10-09 Cardiovascular Res Inst Maastr Organic compounds
CA2560595C (en) 2004-03-29 2013-01-22 Wyeth Multi-vitamin and mineral nutritional supplements
US20060083727A1 (en) 2004-07-15 2006-04-20 Nanobac Pharmaceuticals, Inc. Methods and compositions for the treatment of diseases characterized by calcification and/or plaque formation
PT1728507E (pt) * 2005-06-03 2011-05-27 Nattopharma Asa Utiliza??o de vitamina k para inverter a calcifica??o dos vasos sangu?neos
WO2008006582A1 (en) * 2006-07-14 2008-01-17 Dsm Ip Assets B.V. Compositions comprising magnolol or honokiol and other active agents for the treatment of inflammatory diseases
US8017147B2 (en) * 2008-04-07 2011-09-13 Mazed Mohammad A Nutritional supplement for the prevention of cardiovascular disease, alzheimer's disease, diabetes, and regulation and reduction of blood sugar and insulin resistance
WO2008115783A1 (en) 2007-03-19 2008-09-25 Metaproteomics, Llc Methods and compositions for promoting bone and joint health
RU2440821C2 (ru) * 2007-10-01 2012-01-27 Колгейт-Палмолив Компани Композиции для ухода за полостью рта, содержащие растительные экстракты
CN101239168A (zh) 2008-01-11 2008-08-13 王玉亮 一种具有镇痛抗炎作用的组合物
US20120121730A1 (en) * 2010-10-07 2012-05-17 Trinity Laboratories, Inc. Pharmaceutical and nutraceutical compositions for treating respiratory disease and associated phlegm
US20130017182A1 (en) 2011-07-11 2013-01-17 Natalia Lukina Multi-criteria optimized dietary supplement formulations
US20150056176A1 (en) 2012-01-18 2015-02-26 Stanley N. Jankowitz Anti-inflammatory composition
EP3409280B1 (en) 2012-07-05 2021-04-14 Nutramax Laboratories, Inc. Compositions comprising a sulforaphane and milk thistle extract or powder
EP2549845A3 (de) * 2012-07-31 2013-04-03 Moog Unna GmbH Schaltschrank für ein Pitchsystem
US9138453B2 (en) 2013-10-14 2015-09-22 Biomarker Pharmaceuticals, Inc. Nutrient combinations for affecting an aging process
US20170121268A1 (en) 2014-05-23 2017-05-04 Luiz Antonio Soares Romeiro Ppar modulators
TWI788111B (zh) 2015-01-02 2022-12-21 美商梅拉洛伊卡公司 多元補充品組成物
US9446100B2 (en) 2015-02-13 2016-09-20 Eastern Vision Limited Dietary supplements and formulations
MX2016002359A (es) * 2016-02-23 2017-08-22 Elias Arroyo Paz Francisco Suplemento antienvejecimiento.

Also Published As

Publication number Publication date
US20180042962A1 (en) 2018-02-15
EP3496844A4 (en) 2020-03-18
CN109641183B (zh) 2022-07-12
EP3496844B1 (en) 2024-03-13
US11344575B2 (en) 2022-05-31
AU2017312737B2 (en) 2022-12-22
EP3496844C0 (en) 2024-03-13
WO2018034797A1 (en) 2018-02-22
CN109641183A (zh) 2019-04-16
EP3496844A1 (en) 2019-06-19
AU2017312737A1 (en) 2019-04-04
CA3032792A1 (en) 2018-02-22

Similar Documents

Publication Publication Date Title
MX2019001811A (es) Prevencion y tratamiento de enfermedades de calcificacion vascular y enfermedades asociadas con lo cardiovascular.
PH12021550698A1 (en) Compositions and methods for treating or preventing diseases and/or disorders caused by exposure to air pollution
ECSP12011816A (es) Cepas de lactobacillus plantarum como agentes hipocolesterolémicos
MA31767B1 (fr) Composes organiques et leurs utilisations
MXPA06000318A (es) Pano limpiador y metodos para mejorar la salud de la piel.
MA34909B1 (fr) Triterpénoïdes modifi2s en c-17 et c-3 presentant une activité inhibitrice de la maturation du vih
AR047712A1 (es) Metodo de tratamiento de una lesion de tejido esqueletico blando natural administrando una composicion de celulas madre mesenquimatosas
BRPI0511322A (pt) composições adequadas para o tratamento de sinais cutáneos provenientes do envelhecimento, tablete e formulação de tablete
MA34045B1 (fr) Ligands sigma destinés à être utilisés pour la prévention et/ou le traitement de la douleur postopératoire
WO2005103214A3 (en) Perfume compositions
WO2019030762A3 (en) CANNABIS AND ITS DERIVATIVES FOR THE TREATMENT OF PAIN RELATED TO PAIN AND BONE REGENERATION ASSOCIATED WITH BONE DEFECTS IN THE JAW
NZ600719A (en) Use of a high gluconsinolate cruciferous vegetable for the prevention and/or treatment of a cardiovascular disorder in a human
FR2923355B1 (fr) Utilisation d'une emulsion d'huile de menthe ou de l-carvone pour le traitement fongicide des fruits, legumes ou plantes
Gigante et al. Vitamin MK‐7 enhances vitamin D3‐induced osteogenesis in hMSCs: Modulation of key effectors in mineralization and vascularization
JP2016069317A5 (ja) 腎不全進行抑制剤、腎不全予防剤、尿毒症治療剤、インドキシル硫酸産生阻害剤、心血管系疾患予防剤、及び食品組成物
PH12019501761A1 (en) Potentiated antimicrobial composition for the antimicrobial treatment of biofilms
NO20080170L (no) Pilekstrakt, dens anvendelse og formuleringer inneholdende dem
WO2019050334A3 (ko) 피톤치드를 함유하는 일회용 생리대
AR124639A1 (es) Composición para el tratamiento de una enfermedad vascular, la prevención de una enfermedad vascular, el tratamiento de la hipertensión, o la prevención de la hipertensión
CN105496931A (zh) 一种沐浴露
MX2022005084A (es) Formas sólidas de un modulador del receptor s1p a.
WO2019027299A3 (ko) 간세포성장인자를 발현하는 중간엽줄기세포를 유효성분으로 포함하는 혈관계 질환 예방 또는 치료용 약학 조성물
MX2022016399A (es) Composición agrícola para el tratamiento y prevención de enfermedades y trastornos bacterianos.
MX2021011915A (es) Polimero superabsorbente y metodo para aumentar el contenido de azucar en plantas.
EA201200856A1 (ru) Биологически активная добавка к пище для профилактики заболеваний и оздоровления сердечно-сосудистой системы